more

Loxo Oncology, Inc. (LOXO)

(Delayed Data from NSDQ)

$234.66 USD

0.00 (0.00%)

Updated Feb 14, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta Published on February 13,2019

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

by Zacks Equity Research Published on February 06,2019

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

pharmaceuticals

Is the Options Market Predicting a Spike in Loxo Oncology (LOXO) Stock?

by Zacks Equity Research Published on January 28,2019

Investors need to pay close attention to Loxo Oncology (LOXO) stock based on the movements in the options market lately.

LOXONo Net Change

medical

5 Best Biotech Bets Likely to Outperform Estimates in Q4

by Zacks Equity Research Published on January 23,2019

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

biotechs

Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

by Zacks Equity Research Published on January 09,2019

It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

biotechs

Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo

by Zacks Equity Research Published on January 08,2019

Lilly (LLY) looks to acquire small cancer biotech, Loxo Oncology, to expand its pipeline into targeted cancer therapies.

pharmaceuticals

Company News For Jan 8, 2019

by Zacks Equity Research Published on January 08,2019

Companies In The News Are: LOXO,LLY,DLTR,PCG,MAT

Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors

by Zacks Equity Research Published on November 27,2018

Bayer (BAYRY) receives the FDA approval for larotrectinib for the treatment of adult and pediatric patients having solid tumors with NTRK gene fusion.

pharmaceuticals

Loxo Oncology (LOXO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on November 08,2018

Loxo (LOXO) delivered earnings and revenue surprises of -3128.57% and -1.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

LOXONo Net Change

Loxo Oncology (LOXO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 09,2018

Loxo (LOXO) delivered earnings and revenue surprises of -1500.00% and 7.59%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?